IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Heather A. Wakelee(Palo Alto Institute), Enriqueta Felip(Institut Català d'Ornitologia), Hirotsugu Kenmotsu(Shizuoka Cancer Center), Caicun Zhou(Tongji University), Nasser K. Altorki(Cornell University), Ihor Vynnychenko(Sumy State University), Achim Rittmeyer(Unknown), Martin Reck(German Center for Lung Research), Chenqi Fu(Pennsylvania State University), Tibor Csőszi, Minu K. Srivastava, Shunichi Sugawara(Sendai Kousei Hospital), B.J. Gitlitz, Yu Deng, Elizabeth Bennett, Oleksandr Goloborodko(National University Zaporizhzhia Polytechnic), Marcus Ballinger, Antonio Chella(Azienda Ospedaliera Universitaria Pisana), Yuh-Min Chen(National Yang Ming Chiao Tung University), Alex Martínez‐Martí(Vall d'Hebron Hospital Universitari)
Cited by 22
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k